Physician profile
Stewart Boyd
NPI 1194954578
$4,481.68
in general payments reported to CMS, 2019-2025
28 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $473 · 2021: $709 · 2022: $744 · 2023: $544 · 2024: $515 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.90 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,728.33 | 2019-2024 | Exalt Model D |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.57 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $437.79 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $396.07 | 2019-2025 | Creon, Rinvoq, Skyrizi |
| Fujifilm Healthcare Americas Corporation | $153.55 | 2022 | |
| Ambu INC. | $145.04 | 2020 | |
| Mauna Kea Technologies, INC. | $139.74 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $137.75 | 2022-2025 | Dupixent |
| Conmed Corporation | $135.81 | 2022 | |
| Apollo Endosurgery US INC | $125.66 | 2023 | Overstitch Endoscopic Suturing System |
| Phathom Pharmaceuticals, INC. | $95.31 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $80.41 | 2024-2025 | |
| Ardelyx, INC. | $72.31 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $53.76 | 2024 | Dificid, Zerbaxa |
| Qol Medical, LLC | $43.24 | 2024 | Sucraid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36.63 | 2024-2025 | |
| Covidien LP | $32.80 | 2020 | |
| Ferring Pharmaceuticals INC. | $30.14 | 2023 | Rebyota, Clenpiq |
| Janssen Pharmaceuticals, INC | $28.10 | 2023 | Xarelto |
| Redhill Biopharma INC. | $23.40 | 2021 | |
| Pharmacosmos Therapeutics INC. | $17.25 | 2022 | |
| Endogastric Solutions, INC | $15.95 | 2022 | |
| Celgene Corporation | $15.47 | 2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $15.28 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $14.43 | 2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $13.89 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,161.77 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stewart Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.